Michelle A. Neller

Herston, QLD, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Allogeneic 'off-the-shelf' SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease.

Allogeneic 'off-the-shelf' SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease.

Journal: Clinical & translational immunology
Published: January 31, 2025

Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis.

Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis.

Journal: Clinical & translational immunology
Published: September 08, 2024

Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.

Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.

Journal: Nature communications
Published: May 31, 2024

Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity.

Breakthrough SARS-COV-2 infection induces broad anti-viral T cell immunity.

Journal: iScience
Published: August 07, 2023

Correction: Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients.

Correction: Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients.

Journal: The Journal of experimental medicine
Published: October 25, 2022

Limited Recognition of Highly Conserved Regions of SARS-CoV-2.

Limited Recognition of Highly Conserved Regions of SARS-CoV-2.

Journal: Microbiology spectrum
Published: February 24, 2022

Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3.

Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3.

Journal: Nature communications
Published: January 25, 2022

SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants.

SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants.

Journal: PLoS pathogens
Published: December 17, 2021

Rapid whole-blood assay to detect SARS-CoV-2-specific memory T-cell immunity following a single dose of AstraZeneca ChAdOx1-S COVID-19 vaccine.

Rapid whole-blood assay to detect SARS-CoV-2-specific memory T-cell immunity following a single dose of AstraZeneca ChAdOx1-S COVID-19 vaccine.

Journal: Clinical & translational immunology
Published: July 06, 2021

CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses.

CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses.

Journal: Immunity
Published: January 22, 2021

'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.

'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.

Journal: Journal for immunotherapy of cancer
Published: January 10, 2021

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.

Journal: JCI insight
Published: October 15, 2020
Showing 1-12 of 41

Last Updated: 09/26/2026